Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
AnaptysBio is a special situation that I expect will resolve itself very quickly. In brief, following...
— Matthew Sweeney
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on AnaptysBio, Inc.
AnaptysBio ($ANAB) was recently reconstituted into a biopharmaceutical royalty aggregator following the spin-off of its clinical pipeline into First Tracks Biotherapeutics. The manager initiated...
Operating with extremely low overhead of less than $10 million annually and under ten contract staff, the company features high-margin operations and active share repurchases. Jemperli's sales continue...